INT229085

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.12
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 1
Total Number 2
Disease Relevance 1.72
Pain Relevance 0.68

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (IL1RN, IL1R1) plasma membrane (IL1RN, IL1R1) intracellular (IL1RN, IL1R1)
extracellular space (IL1RN) nucleus (IL1RN) signal transducer activity (IL1R1)
IL1RN (Homo sapiens)
IL1R1 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 28 100.00 Very High Very High Very High
Inflammatory marker 6 93.36 High High
Inflammation 70 88.40 High High
anakinra 8 77.52 Quite High
cytokine 24 5.00 Very Low Very Low Very Low
rheumatoid arthritis 12 5.00 Very Low Very Low Very Low
withdrawal 10 5.00 Very Low Very Low Very Low
depression 4 5.00 Very Low Very Low Very Low
Inflammatory response 4 5.00 Very Low Very Low Very Low
Arthritis 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Atherosclerosis 24 99.80 Very High Very High Very High
INFLAMMATION 76 93.36 High High
Death 10 85.04 High High
Myocardial Infarction 14 84.24 Quite High
Acute Coronary Syndrome 84 79.92 Quite High
Adverse Drug Reaction 24 5.00 Very Low Very Low Very Low
Coronary Artery Disease 14 5.00 Very Low Very Low Very Low
Rheumatoid Arthritis 14 5.00 Very Low Very Low Very Low
Injury 10 5.00 Very Low Very Low Very Low
Pressure And Volume Under Development 8 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Pre-clinical studies indicate that IL-1 may be a primary driver of ACS and that the naturally occurring interleukin-1 receptor antagonist (IL-1ra) may inhibit the atherosclerotic process.
IL-1ra Negative_regulation (inhibit) of Positive_regulation (occurring) of interleukin-1 receptor associated with atherosclerosis and antagonist
1) Confidence 0.12 Published 2008 Journal Trials Section Abstract Doc Link PMC2289802 Disease Relevance 0.86 Pain Relevance 0.34
Pre-clinical studies indicate that IL-1 may be a primary driver of ACS and that the naturally occurring interleukin-1 receptor antagonist (IL-1ra) may inhibit the atherosclerotic process.
antagonist Negative_regulation (inhibit) of Positive_regulation (occurring) of interleukin-1 receptor associated with atherosclerosis and antagonist
2) Confidence 0.10 Published 2008 Journal Trials Section Abstract Doc Link PMC2289802 Disease Relevance 0.86 Pain Relevance 0.34

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox